Our findings indicate that a composite biomarker panel comprising SCC-Ag, CA125, IL-6, and NLR achieves superior predictive performance for both treatment response and survival compared to single-marker models in patients with locally advanced cervical cancer undergoing chemoradiotherapy. This evidence concerns the gene MUC16 and cervical cancer.